MMED MiniMed (MMED) Q1 FY27 earnings call
MiniMed delivered a strong Q1 FY27, exceeding organic growth expectations driven by successful product launches like Flex and increased sensor supply internationally. The company also significantly advanced its pipeline, including early FDA submission for Fit and completion of Vivera's pivotal trial enrollment, reinforcing its leadership in automated insulin delivery and commitment to a comprehensive ecosystem for insulin-taking patients. Management raised its full-year organic revenue growth outlook while reaffirming EBITDA margin guidance, expecting expansion in the second half.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.